Neutrophil Gelatinase-Associated Lipocalin (NGAL): an early marker for diabetic nephropathy
- 29 February 2012
- journal article
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 32 (1) , 19-24
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Neutrophil Gelatinase-Associated Lipocalin as an Early Biomarker of Nephropathy in Diabetic PatientsKidney and Blood Pressure Research, 2009
- Neutrophil Gelatinase-Associated Lipocalin Reflects the Severity of Renal Impairment in Subjects Affected by Chronic Kidney DiseaseKidney and Blood Pressure Research, 2008
- Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritisPediatric Nephrology, 2008
- Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damageKidney International, 2007
- N-GAL: Diagnosing AKI as soon as possibleCritical Care, 2007
- Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney diseasePediatric Nephrology, 2007
- Emerging Biomarkers of Acute Kidney Injury2007
- Standards of Medical Care in DiabetesDiabetes Care, 2004
- Molecular Characterization and Pattern of Tissue Expression of the Gene for Neutrophil Gelatinase-Associated Lipocalin from HumansGenomics, 1997
- Serum measurements of human neutrophil lipocalin (HNL) discriminate between acute bacterial and viral infectionsScandinavian Journal of Clinical and Laboratory Investigation, 1995